Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
Agnès Girard(Pfizer (United States)), James A. Retsema(Pfizer (United States)), C. R. Cimochowski(Pfizer (United States)), J. A. Faiella(Pfizer (United States)), Thomas D. Gootz(Pfizer (United States)), D Girard(Pfizer (United States)), S L Haskell(Pfizer (United States)), A. R. English(Pfizer (United States))
Cited by 323
Related Papers
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
|Antimicrobial Agents and Chemotherapy|1987|461
CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization
|Antimicrobial Agents and Chemotherapy|1978|397
<b>Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, <i>mefA</i>, from <i>Streptococcus pyogenes</i></b>
|Molecular Microbiology|1996|360
Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; A new class of macrolide antibiotics, the azalides.
|The Journal of Antibiotics|1988|238
Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection
|Antimicrobial Agents and Chemotherapy|1996|154